Cargando…

TBC1D15 deficiency protects against doxorubicin cardiotoxicity via inhibiting DNA-PKcs cytosolic retention and DNA damage

Clinical application of doxorubicin (DOX) is heavily hindered by DOX cardiotoxicity. Several theories were postulated for DOX cardiotoxicity including DNA damage and DNA damage response (DDR), although the mechanism(s) involved remains to be elucidated. This study evaluated the potential role of TBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Wenjun, Xu, Haixia, Sun, Zhe, Du, Yuxin, Sun, Shiqun, Abudureyimu, Miyesaier, Zhang, Mengjiao, Tao, Jun, Ge, Junbo, Ren, Jun, Zhang, Yingmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692480/
https://www.ncbi.nlm.nih.gov/pubmed/38045047
http://dx.doi.org/10.1016/j.apsb.2023.09.008
_version_ 1785152950789734400
author Yu, Wenjun
Xu, Haixia
Sun, Zhe
Du, Yuxin
Sun, Shiqun
Abudureyimu, Miyesaier
Zhang, Mengjiao
Tao, Jun
Ge, Junbo
Ren, Jun
Zhang, Yingmei
author_facet Yu, Wenjun
Xu, Haixia
Sun, Zhe
Du, Yuxin
Sun, Shiqun
Abudureyimu, Miyesaier
Zhang, Mengjiao
Tao, Jun
Ge, Junbo
Ren, Jun
Zhang, Yingmei
author_sort Yu, Wenjun
collection PubMed
description Clinical application of doxorubicin (DOX) is heavily hindered by DOX cardiotoxicity. Several theories were postulated for DOX cardiotoxicity including DNA damage and DNA damage response (DDR), although the mechanism(s) involved remains to be elucidated. This study evaluated the potential role of TBC domain family member 15 (TBC1D15) in DOX cardiotoxicity. Tamoxifen-induced cardiac-specific Tbc1d15 knockout (Tbc1d15(CKO)) or Tbc1d15 knockin (Tbc1d15(CKI)) male mice were challenged with a single dose of DOX prior to cardiac assessment 1 week or 4 weeks following DOX challenge. Adenoviruses encoding TBC1D15 or containing shRNA targeting Tbc1d15 were used for Tbc1d15 overexpression or knockdown in isolated primary mouse cardiomyocytes. Our results revealed that DOX evoked upregulation of TBC1D15 with compromised myocardial function and overt mortality, the effects of which were ameliorated and accentuated by Tbc1d15 deletion and Tbc1d15 overexpression, respectively. DOX overtly evoked apoptotic cell death, the effect of which was alleviated and exacerbated by Tbc1d15 knockout and overexpression, respectively. Meanwhile, DOX provoked mitochondrial membrane potential collapse, oxidative stress and DNA damage, the effects of which were mitigated and exacerbated by Tbc1d15 knockdown and overexpression, respectively. Further scrutiny revealed that TBC1D15 fostered cytosolic accumulation of the cardinal DDR element DNA-dependent protein kinase catalytic subunit (DNA-PKcs). Liquid chromatography–tandem mass spectrometry and co-immunoprecipitation denoted an interaction between TBC1D15 and DNA-PKcs at the segment 594–624 of TBC1D15. Moreover, overexpression of TBC1D15 mutant (∆594–624, deletion of segment 594–624) failed to elicit accentuation of DOX-induced cytosolic retention of DNA-PKcs, DNA damage and cardiomyocyte apoptosis by TBC1D15 wild type. However, Tbc1d15 deletion ameliorated DOX-induced cardiomyocyte contractile anomalies, apoptosis, mitochondrial anomalies, DNA damage and cytosolic DNA-PKcs accumulation, which were canceled off by DNA-PKcs inhibition or ATM activation. Taken together, our findings denoted a pivotal role for TBC1D15 in DOX-induced DNA damage, mitochondrial injury, and apoptosis possibly through binding with DNA-PKcs and thus gate-keeping its cytosolic retention, a route to accentuation of cardiac contractile dysfunction in DOX-induced cardiotoxicity.
format Online
Article
Text
id pubmed-10692480
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106924802023-12-03 TBC1D15 deficiency protects against doxorubicin cardiotoxicity via inhibiting DNA-PKcs cytosolic retention and DNA damage Yu, Wenjun Xu, Haixia Sun, Zhe Du, Yuxin Sun, Shiqun Abudureyimu, Miyesaier Zhang, Mengjiao Tao, Jun Ge, Junbo Ren, Jun Zhang, Yingmei Acta Pharm Sin B Original Article Clinical application of doxorubicin (DOX) is heavily hindered by DOX cardiotoxicity. Several theories were postulated for DOX cardiotoxicity including DNA damage and DNA damage response (DDR), although the mechanism(s) involved remains to be elucidated. This study evaluated the potential role of TBC domain family member 15 (TBC1D15) in DOX cardiotoxicity. Tamoxifen-induced cardiac-specific Tbc1d15 knockout (Tbc1d15(CKO)) or Tbc1d15 knockin (Tbc1d15(CKI)) male mice were challenged with a single dose of DOX prior to cardiac assessment 1 week or 4 weeks following DOX challenge. Adenoviruses encoding TBC1D15 or containing shRNA targeting Tbc1d15 were used for Tbc1d15 overexpression or knockdown in isolated primary mouse cardiomyocytes. Our results revealed that DOX evoked upregulation of TBC1D15 with compromised myocardial function and overt mortality, the effects of which were ameliorated and accentuated by Tbc1d15 deletion and Tbc1d15 overexpression, respectively. DOX overtly evoked apoptotic cell death, the effect of which was alleviated and exacerbated by Tbc1d15 knockout and overexpression, respectively. Meanwhile, DOX provoked mitochondrial membrane potential collapse, oxidative stress and DNA damage, the effects of which were mitigated and exacerbated by Tbc1d15 knockdown and overexpression, respectively. Further scrutiny revealed that TBC1D15 fostered cytosolic accumulation of the cardinal DDR element DNA-dependent protein kinase catalytic subunit (DNA-PKcs). Liquid chromatography–tandem mass spectrometry and co-immunoprecipitation denoted an interaction between TBC1D15 and DNA-PKcs at the segment 594–624 of TBC1D15. Moreover, overexpression of TBC1D15 mutant (∆594–624, deletion of segment 594–624) failed to elicit accentuation of DOX-induced cytosolic retention of DNA-PKcs, DNA damage and cardiomyocyte apoptosis by TBC1D15 wild type. However, Tbc1d15 deletion ameliorated DOX-induced cardiomyocyte contractile anomalies, apoptosis, mitochondrial anomalies, DNA damage and cytosolic DNA-PKcs accumulation, which were canceled off by DNA-PKcs inhibition or ATM activation. Taken together, our findings denoted a pivotal role for TBC1D15 in DOX-induced DNA damage, mitochondrial injury, and apoptosis possibly through binding with DNA-PKcs and thus gate-keeping its cytosolic retention, a route to accentuation of cardiac contractile dysfunction in DOX-induced cardiotoxicity. Elsevier 2023-12 2023-09-17 /pmc/articles/PMC10692480/ /pubmed/38045047 http://dx.doi.org/10.1016/j.apsb.2023.09.008 Text en © 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Yu, Wenjun
Xu, Haixia
Sun, Zhe
Du, Yuxin
Sun, Shiqun
Abudureyimu, Miyesaier
Zhang, Mengjiao
Tao, Jun
Ge, Junbo
Ren, Jun
Zhang, Yingmei
TBC1D15 deficiency protects against doxorubicin cardiotoxicity via inhibiting DNA-PKcs cytosolic retention and DNA damage
title TBC1D15 deficiency protects against doxorubicin cardiotoxicity via inhibiting DNA-PKcs cytosolic retention and DNA damage
title_full TBC1D15 deficiency protects against doxorubicin cardiotoxicity via inhibiting DNA-PKcs cytosolic retention and DNA damage
title_fullStr TBC1D15 deficiency protects against doxorubicin cardiotoxicity via inhibiting DNA-PKcs cytosolic retention and DNA damage
title_full_unstemmed TBC1D15 deficiency protects against doxorubicin cardiotoxicity via inhibiting DNA-PKcs cytosolic retention and DNA damage
title_short TBC1D15 deficiency protects against doxorubicin cardiotoxicity via inhibiting DNA-PKcs cytosolic retention and DNA damage
title_sort tbc1d15 deficiency protects against doxorubicin cardiotoxicity via inhibiting dna-pkcs cytosolic retention and dna damage
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692480/
https://www.ncbi.nlm.nih.gov/pubmed/38045047
http://dx.doi.org/10.1016/j.apsb.2023.09.008
work_keys_str_mv AT yuwenjun tbc1d15deficiencyprotectsagainstdoxorubicincardiotoxicityviainhibitingdnapkcscytosolicretentionanddnadamage
AT xuhaixia tbc1d15deficiencyprotectsagainstdoxorubicincardiotoxicityviainhibitingdnapkcscytosolicretentionanddnadamage
AT sunzhe tbc1d15deficiencyprotectsagainstdoxorubicincardiotoxicityviainhibitingdnapkcscytosolicretentionanddnadamage
AT duyuxin tbc1d15deficiencyprotectsagainstdoxorubicincardiotoxicityviainhibitingdnapkcscytosolicretentionanddnadamage
AT sunshiqun tbc1d15deficiencyprotectsagainstdoxorubicincardiotoxicityviainhibitingdnapkcscytosolicretentionanddnadamage
AT abudureyimumiyesaier tbc1d15deficiencyprotectsagainstdoxorubicincardiotoxicityviainhibitingdnapkcscytosolicretentionanddnadamage
AT zhangmengjiao tbc1d15deficiencyprotectsagainstdoxorubicincardiotoxicityviainhibitingdnapkcscytosolicretentionanddnadamage
AT taojun tbc1d15deficiencyprotectsagainstdoxorubicincardiotoxicityviainhibitingdnapkcscytosolicretentionanddnadamage
AT gejunbo tbc1d15deficiencyprotectsagainstdoxorubicincardiotoxicityviainhibitingdnapkcscytosolicretentionanddnadamage
AT renjun tbc1d15deficiencyprotectsagainstdoxorubicincardiotoxicityviainhibitingdnapkcscytosolicretentionanddnadamage
AT zhangyingmei tbc1d15deficiencyprotectsagainstdoxorubicincardiotoxicityviainhibitingdnapkcscytosolicretentionanddnadamage